AVACTA GROUP PLC LS-,10

Avacta Therapeutics has published the annual report for the year ended 31 December 2025 and convened the annual general meeting for Monday, 22 June 2026 at 09:00 BST at Glaziers Hall, London. Shareholders who chose postal distribution will receive the papers today; registered shareholders may attend in person or be represented by a proxy. Attendance requires pre-registration and proof of share ownership by email by 20 June 2026, 20:00 BST, although failure to register does not prevent attendance or appointment of a proxy. After the meeting Avacta plans to give an update on business developments; presentation materials and a recording will be made available on the website. » Więcej na de.investing.com

Avacta announced that CEO Christina Coughlin was included on the "Rising Leaders 2026" list by the trade publication In Vivo. Coughlin, MD PhD, has led the company for two years and previously worked as an oncologist. Chairman Shaun Chilton emphasized that under Coughlin's leadership the drug candidate AVA6103 was advanced from research to treatment of the first patients in a phase‑1a study within 24 months. » Więcej na de.investing.com

Avacta will raise about £10m by placing 15m new shares plus 873,016 shares in a subscription at 63 pence each (9.35% discount). The proceeds are intended to serve as working capital to fund research and development programmes into early Q1 2027 and to extend the runway through the first readout of the Phase‑1a study of AVA6103 (first readout end‑2026). Dosing of AVA6103 is imminent, Phase‑1b expansion cohorts for Faridoxorubicin are nearly recruited; two non‑executive directors intend to participate in the subscription and Zeus Capital is acting as broker, with an accelerated bookbuild having been launched. » Więcej na de.investing.com